CN101375978A - Medicinal composition for lowering blood fat - Google Patents
Medicinal composition for lowering blood fat Download PDFInfo
- Publication number
- CN101375978A CN101375978A CNA2007101210543A CN200710121054A CN101375978A CN 101375978 A CN101375978 A CN 101375978A CN A2007101210543 A CNA2007101210543 A CN A2007101210543A CN 200710121054 A CN200710121054 A CN 200710121054A CN 101375978 A CN101375978 A CN 101375978A
- Authority
- CN
- China
- Prior art keywords
- weight portion
- preparation
- piperis longi
- fructus piperis
- fructus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008280 blood Substances 0.000 title claims abstract description 46
- 210000004369 blood Anatomy 0.000 title claims abstract description 45
- 239000000203 mixture Substances 0.000 title claims abstract description 18
- 239000003814 drug Substances 0.000 claims abstract description 38
- 229940079593 drug Drugs 0.000 claims abstract description 17
- 230000000694 effects Effects 0.000 claims abstract description 17
- 238000002360 preparation method Methods 0.000 claims abstract description 17
- 238000002156 mixing Methods 0.000 claims abstract description 7
- 235000013402 health food Nutrition 0.000 claims abstract description 3
- 239000000284 extract Substances 0.000 claims description 19
- 239000000843 powder Substances 0.000 claims description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 17
- 239000002775 capsule Substances 0.000 claims description 14
- 239000000341 volatile oil Substances 0.000 claims description 11
- 239000008187 granular material Substances 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 238000005303 weighing Methods 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 239000006071 cream Substances 0.000 claims description 5
- 239000006187 pill Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 4
- -1 electuary Substances 0.000 claims description 3
- 239000003921 oil Substances 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 239000007779 soft material Substances 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 239000006196 drop Substances 0.000 claims description 2
- 238000005469 granulation Methods 0.000 claims description 2
- 230000003179 granulation Effects 0.000 claims description 2
- 238000001256 steam distillation Methods 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 2
- 239000012567 medical material Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 238000007873 sieving Methods 0.000 claims 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 14
- 150000002632 lipids Chemical class 0.000 abstract description 13
- 239000002994 raw material Substances 0.000 abstract description 10
- 239000000546 pharmaceutical excipient Substances 0.000 abstract description 5
- 239000002552 dosage form Substances 0.000 abstract description 4
- 239000004480 active ingredient Substances 0.000 abstract description 2
- 235000012000 cholesterol Nutrition 0.000 abstract description 2
- 241000049624 Alisma plantago-aquatica subsp. orientale Species 0.000 abstract 1
- 235000017159 Crataegus pinnatifida Nutrition 0.000 abstract 1
- 241000657480 Crataegus pinnatifida Species 0.000 abstract 1
- 235000019510 Long pepper Nutrition 0.000 abstract 1
- 240000003455 Piper longum Species 0.000 abstract 1
- 241001648835 Polygonum cuspidatum Species 0.000 abstract 1
- 241000405911 Rehmannia glutinosa Species 0.000 abstract 1
- 235000018167 Reynoutria japonica Nutrition 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 16
- 230000001737 promoting effect Effects 0.000 description 12
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 11
- 210000002784 stomach Anatomy 0.000 description 10
- 235000013305 food Nutrition 0.000 description 9
- 201000005577 familial hyperlipidemia Diseases 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 7
- 230000017531 blood circulation Effects 0.000 description 6
- 208000031226 Hyperlipidaemia Diseases 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 108700022737 rat Fat1 Proteins 0.000 description 4
- 210000000582 semen Anatomy 0.000 description 4
- 241000721047 Danaus plexippus Species 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 235000021028 berry Nutrition 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 238000002481 ethanol extraction Methods 0.000 description 2
- 239000000469 ethanolic extract Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- 240000000920 Typhonium flagelliforme Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229940060038 chlorine Drugs 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 229960002297 fenofibrate Drugs 0.000 description 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
- 229960003627 gemfibrozil Drugs 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000009427 jiangzhi Substances 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a Chinese medicinal composition with the effect of reducing blood lipid, which comprises Crataegus pinnatifida, Alisma orientalis, Polygonum cuspidatum, Piper longum and Rehmannia glutinosa. The preparation method of the composition comprises the following steps: extracting active ingredients from raw materials, mixing with a specified amount of one or more pharmaceutically acceptable medical adjuvants or excipients according to a certain proportion, and making into a desired dosage form. The composition with the effect of reducing blood lipid can distinctly reduce the contents of plasma cholesterol and low density cholesterol, and also can be used for preparing medicines and health foods for reducing blood lipid.
Description
Technical field
The invention belongs to the field of Chinese medicines, be specifically related to a kind of Chinese medicine compound of being made up of Fructus Crataegi, Rhizoma Alismatis, Rhizoma Polygoni Cuspidati, Fructus Piperis Longi and Radix Rehmanniae Preparata, compound recipe of the present invention has the effect of blood fat reducing.
Background technology
Hyperlipemia belongs to commonly encountered diseases in clinical, with advancing age, its sickness rate also obviously increases, and is particularly common in obese people.Hyperlipemia plays an important role in arteriosclerosis, cause of coronary heart disease mechanism, causes people's common concern, the control of cardiovascular and cerebrovascular disease is brought in the government utility in China, puts on an equal footing with the infectious disease control.Over nearly 20 years, blood-fat regulating medicine is of a great variety, according to the difference of main therapeutical effect, roughly is divided into two big classes: to reduce the Statins that pushes away that blood T-CHOL and low density lipoprotein, LDL are main head, cut down his spit of fland as simvastatin, pravastatin and chlorine; Another kind of is based on triglyceride reducing, is representative with the special class of shellfish, and as fenofibrate and gemfibrozil etc., they are line medicines of control dyslipidemia, have the effect of high density lipoprotein increasing.Except that some chemical medicines, the Chinese patent medicine that is used for hyperlipidemia is also more, as SHANZHAJING JIANGZHI PIAN, extracts active component by Fructus Crataegi and makes, and is used for the interior card that stagnates of the food stasis of blood of hyperlipidemia; But the fat clearing capsule is made up of Semen Lepidii, Radix Scutellariae, Fructus Crataegi, Radix Et Rhizoma Rhei, Rhizoma Alismatis, the Radix Aucklandiae, is used for accumulateing disease in the phlegm-damp of hyperlipidemia; The Yunnan pollen tianqi oral liquid is made up of pollen of Semen Fagopyri Esculenti, Typhonium flagelliforme (Lodd.) Blume, Mel, is used for the syndrome of static blood blocking collaterals of hyperlipemia, class this also have a lot.Publication aspect, CN1263772A discloses a kind of capsule for descend of blood fat, it is made up of Fructus Crataegi, the Radix Polygoni Multiflori, Rhizoma Alismatis, Radix Bupleuri, Radix Salviae Miltiorrhizae, Pericarpium Citri Reticulatae, Semen Raphani, Radix Curcumae, has that strengthening spleen, tonifying kidney is soothing the liver, a promoting blood circulation to remove stagnancy blood stasis dispelling effect treatment fatty liver, and the hyperlipemia effect is better; CN1364512A discloses a kind of defatting and poison expelling capsule, selects Radix Et Rhizoma Rhei, the Radix Polygoni Multiflori, Semen Cassiae, Rhizoma Alismatis for use, through ethanol extraction, Fructus Gardeniae, Radix Bupleuri, Rhizoma Curcumae, Fructus Crataegi, Herba Artemisiae Scopariae water are carried, make capsule, it can treat and prevent hyperlipemia, blood fat reducing, elimination hemorheology obstacle.CN1283288C discloses a kind of preparation method of capsule for descend of blood fat, this capsule is to be prepared from by Radix Puerariae, Fructus Crataegi, Rhizoma Alismatis, Radix Polygoni Multiflori and Radix Angelicae Sinensis, have promoting digestion and removing stagnation, blood circulation promoting and blood stasis dispelling, strengthening spleen, tonifying kidney, clearing away heat-damp and promoting diuresis effect, be used for the treatment of hyperlipidemia, can reach the effect for the treatment of both the principal and the secondary aspects of a disease at the same time.
Summary of the invention
The object of the present invention is to provide a kind of blood fat reducing Chinese medicine composition of determined curative effect.
Another object of the present invention also is to provide a kind of method for preparing this blood fat reducing Chinese medicine composition active component.
Blood fat reducing Chinese medicine composition of the present invention is that crude drug is formed by following weight portion: Fructus Crataegi 8-30 weight portion, Rhizoma Alismatis 5-14 weight portion, Rhizoma Polygoni Cuspidati 1-10 weight portion, Fructus Piperis Longi 1-10 weight portion, Radix Rehmanniae Preparata 1-10 weight portion; Be preferably Fructus Crataegi 10-20 weight portion, Rhizoma Alismatis 8-12 weight portion, Rhizoma Polygoni Cuspidati 5-10 weight portion, Fructus Piperis Longi 5-10 weight portion, Radix Rehmanniae Preparata 5-10 weight portion, Fructus Crataegi 15 weight portions more preferably, Rhizoma Alismatis 10 weight portions, Rhizoma Polygoni Cuspidati 8 weight portions, Fructus Piperis Longi 6 weight portions, Radix Rehmanniae Preparata 6 weight portions.
Among the present invention, Fructus Crataegi can be a haw berry, also can be Folium Crataegi, and haw berry is strong than the Fructus Crataegi effect with Fructus Crataegi (parched).Radix Rehmanniae is selected Radix Rehmanniae Preparata for use.
Among the we, Fructus Crataegi has the effect of promoting digestion and removing stagnation, invigorating the spleen and regulating the stomach, blood circulation promoting and blood stasis dispelling, is monarch drug in the side; Rhizoma Alismatis is apt to the promoting diuresis to eliminate damp pathogen heat clearing away, is ministerial drug in the side, assists monarch drug, makes its blood stasis dispelling blood and does not go up fresh blood, and dissipating depression of QI gas and do not hinder healthy energy makes heresy that outlet be arranged, jointly at primary symptom; Assistant is with Rhizoma Polygoni Cuspidati promoting blood circulation to remove blood stasis, dispelling wind and removing obstruction in the collateral, clearing away heat-damp and promoting diuresis, and Fructus Piperis Longi warming spleen and stomach for dispelling cold, therapeutic method to keep the adverse QI flowing downwards pain relieving remove vomiting, eliminate the phlegm and the dyspepsia that disappears with the warming the spleen stomach, thereby assists the promoting blood circulation to remove blood stasis of monarch drug, the merit of promoting digestion and removing stagnation; Make with Radix Rehmanniae Preparata, the YIN nourishing of can enriching blood, beneficial essence are filled out marrow, and promoting tissue regeneration by removing blood stasis makes blood fortune unimpeded.More than all medicines share, reinforcing and reducing are also executed, the effect that row stagnates and to promote blood circulation is played in treating both the principal and the secondary aspects of a disease at the same time altogether.
In the prescription of the present invention, each single medicinal material can be through respectively behind physical pulverization, merging mixing and be used as medicine with the medicinal powder form, also can merge after extracting each crude drug effective ingredient and be used as medicine, can also be to be used as medicine with other medicine dried cream powder form after extracting after the part medicine is pulverized again.When extracting each crude drug active component, crude drug can merge through decocting and boils or ethanol extraction, also can be to extract respectively separately to remerge behind the effective ingredient.
Blood fat reducing Chinese medicine composition active component of the present invention adds pharmaceutic adjuvant acceptable and excipient in the suitable pharmacy, can be prepared into various needed pharmaceutical dosage forms.Among the present invention, the drug prepared dosage form is preferably peroral dosage form, as tablet, capsule, granule, oral liquid, electuary, pill, powder, suspension, drop pill etc., more preferably capsule.
Be ground into fine powder as raw material of Chinese medicine of the present invention, merge evenly, pack powder.
After raw material of Chinese medicine of the present invention, water decoct, be condensed into relative density and be 1.15 concentrated solution, add an amount of correctives and antiseptic, make syrup or mixed-blood liquid.
Raw material of Chinese medicine of the present invention is directly pulverized the encapsulated capsule that gets in back; Or raw material of Chinese medicine of the present invention is behind effective component extracting, and effective ingredient is directly pulverized, in the hard capsule case of packing into, capsule; Or the active component of the present invention after extracting, joining in the fused Polyethylene Glycol, mixing splashes in the refrigerative liquid paraffin, can be made into drop pill.
Blood fat reducing Chinese medicine composition compound recipe extracts active ingredients of the present invention can realize in the following way:
Take by weighing each crude drug by weight, standby.
Rhizoma Alismatis powder is broken into coarse powder, soak with ethanol, respectively with the alcohol reflux three times of 10,8,8 times of amount 70%-95%, each 1.5 hours, filter, merge ethanol extract, be evaporated to the extractum shape, Rhizoma Alismatis extractum extract I.
Fructus Piperis Longi powder is broken into coarse powder, measures distilled water immersions with 12 times and spends the night, and extracts Fructus Piperis Longi volatile oil with steam distillation, collects the profit phase, leaves standstill the back and separates oil phase, and oil phase gets Fructus Piperis Longi volatile oil with anhydrous sodium sulfate dehydration, and is standby.
Fructus Crataegi, Rhizoma Polygoni Cuspidati, Radix Rehmanniae Preparata are soaked, and add the Fructus Piperis Longi after extracting volatile oil, with the water boiling and extraction of 10 times of amounts 3 times, merge water boiling and extraction liquid, concentrating under reduced pressure, extractum II.
Extractum I and extractum II are merged, mixing, drying is pulverized, and gets compositions extract dried cream powder.
Dried cream is made soft material with 75% ethanol, and granulation is sieved, drying, granulate, evenly spray Fructus Piperis Longi volatile oil after, add suitable pharmaceutical aids and excipient, make required preparation.
The present composition proves through pharmacological experiment study, can reduce the serum total cholesterol (TC) of experimental hyperlipemia rat and rabbit and the content of triglyceride (TG), change hyperlipemia rat hemorheology form, reduce its blood viscosity, and high density lipoprotein increasing that can be suitable (HDL-C) level, have significantly effect for reducing blood fat, can be used for preparing blood lipid-lowering medicine and health food.
Specific embodiment
Preparation embodiment
Below further specify technical scheme of the present invention from the preparation of activity extract of the present invention
Embodiment 1
Take by weighing following raw materials in weight: Fructus Crataegi 1500g, Rhizoma Alismatis 1000g, Rhizoma Polygoni Cuspidati 800g, Fructus Piperis Longi 600g, Radix Rehmanniae Preparata 600g, standby;
Rhizoma Alismatis powder is broken into coarse powder, and 85% ethanol soaks into, and 8 times of amount solvent refluxings extract 3 times, and each 1.5 hours, filter, merge ethanol extract, concentrating under reduced pressure gets concentrated solution I;
Fructus Piperis Longi is pulverized, and water is dipped to, and extracts Fructus Piperis Longi volatile oil with vapor distillation, collects Fructus Piperis Longi volatile oil, and is standby;
With Fructus Crataegi, Rhizoma Polygoni Cuspidati, Radix Rehmanniae Preparata pulverizing medicinal materials, merge, to soak, the Fructus Piperis Longi medicinal residues behind the volatile oil are extracted in adding, decoct to extract 3 times, each 1.5 hours, merge decocting liquid, concentrating under reduced pressure gets concentrated solution II;
Merge concentrated solution I, II, mixing, vacuum drying is pulverized, and sieves, and gets the activity extract powder;
The activity extract powder is made soft material with 75% ethanol, granulate, drying is sieved, drying, and granulate, the volatile oil that extraction is obtained sprays in the whole good granule, and mixing in No. 1 capsule of packing into, promptly gets capsule; Add additive of tablet, tabletting can get tablet; Perhaps directly pack gets granule.
Embodiment 2
Take by weighing following raw materials in weight: Fructus Crataegi 3000g, Rhizoma Alismatis 800g, Rhizoma Polygoni Cuspidati 500g, Fructus Piperis Longi 500g, Radix Rehmanniae Preparata 500g, standby;
Preparation process is with embodiment 1
Embodiment 3
Take by weighing following raw materials in weight: Fructus Crataegi 800g, Rhizoma Alismatis 1200g, Rhizoma Polygoni Cuspidati 500g, Fructus Piperis Longi 500g, Radix Rehmanniae Preparata 500g, standby;
Preparation process is with embodiment 1
Embodiment 4
Take by weighing following raw materials in weight: Fructus Crataegi 2000g, Rhizoma Alismatis 1000g, Rhizoma Polygoni Cuspidati 1000g, Fructus Piperis Longi 1000g, Radix Rehmanniae Preparata 1000g, standby;
Preparation process is with embodiment 1
Embodiment 5
Take by weighing following raw materials in weight: Fructus Crataegi 2500g, Rhizoma Alismatis 1100g, Rhizoma Polygoni Cuspidati 900g, Fructus Piperis Longi 700g, Radix Rehmanniae Preparata 700g, standby;
Preparation process is with embodiment 1
Pharmacology embodiment
Below from the pharmacology embodiment of the present composition beneficial effect of the present invention is described.In following examples, serving as the experiment medicine with the extract active component of embodiment 1 gained, but not merely be the active component that is limited to this ratio gained, only is in order to save space, beneficial effect of the present invention to be described at this.
1, to the influence of experimental hyperlipemia rat blood fat
(1) animal and grouping: laboratory animal, 40 of male Waster rats were for 6 ages in week, available from Beijing University's medical college Experimental Animal Center.After experimental rat given normal feedstuff and raise 7 days in advance, anesthetized rat, external jugular vein blood drawing 3mL detects the blood fat of every group of rat before the treatment respectively, press the TC level, animal is divided at random blank group, matched group, the present invention are heavy dose ofly organized, small dose group.
(2) preparation of experiment medicine: high lipid food: by normal feedstuff 78.8%, Adeps Sus domestica 10%, cholesterol 1%, yolk powder 10%, cholate 0.2% is formed; Extract of the present invention: the heavy dose of group of rat is irritated stomach every day and is given 4.8g/kg dosage for Coming-of-Age Day 15 times of consumption; Small dose group is Coming-of-Age Day 3.75 times of consumption, day not give 1.2g/kg dosage, irritates stomach 2mL; Blank group and matched group all give isopyknic normal saline.
(3) experimental technique: blank group gives normal feedstuff, and matched group gives high lipid food, and heavy dose of group, small dose group give high lipid food, and irritate stomach extract medicinal liquid of the present invention simultaneously, and continuous 25 days, whole filling stomach process was smooth, no abnormal reaction.The filling stomach is given the rat fasting and is weighed after 25 days, fasting second day through postcava blood drawing 5mL, detects blood fat and the hemorheology value of every group of rat respectively.
(4) experimental result: to the influence of rat fat, see Table 1～3, by the table result as can be known, give high lipid food after, model group and blank group relatively, Serum TC (T-CHOL), TG (triglyceride) level obviously increase, and show that high blood lipid model sets up; To the influence of hemorheology of rat, see Table 4, the result shows, model group and blank group relatively, the hemorheology of rat height cut viscosity, in cut viscosity, lowly cut viscosity and significantly increase, show that the high blood lipid model viscosity increases.
The influence of table 1 couple rat fat TC (x ± s, n=10)
Compare with the blank group,
#P＜0.01; Compare with model group,
*P＜0.05,
*P＜0.01
The influence of table 2 couple rat fat TG (x ± s, n=10)
Compare with the blank group,
#P＜0.01; Compare with model group,
*P＜0.05
The influence of table 3 couple rat fat HDL-C (x ± s, n=10)
The influence of table 4 pair hemorheology of rat (x ± s, n=10)
Compare with the blank group,
#P＜0.05,
##P＜0.01; Compare with model group,
*P＜0.05,
*P＜0.01
Respectively show the result as can be known from last, the large and small dosage group of the present invention all can significantly reduce Serum TC, TG level (P＜0.05 or P＜0.01), to the influence of rat HDL-C level, there was no significant difference.From hemorheological angle, the present composition can large and small dosage group all can significantly reduce the rat blood height cut viscosity and in cut viscosity (P＜0.05 or P＜0.01), heavy dose of group can significantly reduce to hang down cuts viscosity (P＜0.01), but small dose group is to the low no significance of viscosity influence of cutting of rat blood.
2, to the influence of experimental rabbit blood fat
Get 20 of rabbit, the male and female dual-purpose, body weight 1.85 ± 0.27kg is divided into 4 groups at random, 5 every group, is divided into: normal control group, feed normal feedstuff; High fat matched group: feed high lipid food; High dose present composition group, the feed high lipid food, per kilogram of body weight is irritated stomach extract 4.8g of the present invention simultaneously; Low dosage extract group of the present invention, the feed high lipid food, per kilogram of body weight is irritated stomach extract 1.2g of the present invention simultaneously.High lipid food is formed the same.The animal sub-cage rearing, behind 14 days, 28 days after the administration, respectively by ear edge vein exploitating blood, separation of serum is measured serum total cholesterol TC, triglyceride TG, observes each group and changes.Experimental result shows, behind oral present composition 14d of rabbit and the 18d, hyperlipidemia model matched group group is compared serum total cholesterol content and content of triglyceride with the normal control group have significant difference (P＜0.01), give the extract of the present invention of various dose, compare with high fat matched group, all can reduce the content of serum total cholesterol and triglyceride, difference has significance (P＜0.01).Experimental result sees Table 5
Table 5 present composition to the influence of rabbit blood fat (x ± s, n=5)
Compare with normal control,,
##P＜0.01; Compare with model control group,
*P＜0.01
Claims (10)
1, a kind of pharmaceutical composition of blood fat reducing is characterized in that being made up of following bulk drugs: Fructus Crataegi 8-30 weight portion, Rhizoma Alismatis 5-14 weight portion, Rhizoma Polygoni Cuspidati 1-10 weight portion, Fructus Piperis Longi 1-10 weight portion, Radix Rehmanniae Preparata 1-10 weight portion.
2, pharmaceutical composition as claimed in claim 1 is characterized in that being made up of following bulk drugs: Fructus Crataegi 10-20 weight portion, Rhizoma Alismatis 8-12 weight portion, Rhizoma Polygoni Cuspidati 5-10 weight portion, Fructus Piperis Longi 5-10 weight portion, Radix Rehmanniae Preparata 5-10 weight portion.
3, pharmaceutical composition as claimed in claim 2 is characterized in that being made up of following bulk drugs: Fructus Crataegi 15 weight portions, Rhizoma Alismatis 10 weight portions, Rhizoma Polygoni Cuspidati 8 weight portions, Fructus Piperis Longi 6 weight portions, Radix Rehmanniae Preparata 6 weight portions.
4, a kind of is the pharmaceutical preparation that main active is made by claim 1,2 or 3 described pharmaceutical compositions.
5, preparation as claimed in claim 4 is characterized in that described preparation is an oral formulations.
6, preparation as claimed in claim 5 is characterized in that described oral formulations is mainly tablet, capsule, granule, oral liquid, electuary, pill, powder, suspension, drop pill.
7, preparation as claimed in claim 6 is characterized in that capsule.
8, preparation is characterized in that comprising the steps: as the method for claim 1,2 or 3 described pharmaceutical composition active component
(1) take by weighing medical material by weight, standby;
(2) Rhizoma Alismatis powder is broken into coarse powder, soak with ethanol, and reflux, extract, 3 times, merge extractive liquid,, concentrating under reduced pressure gets Rhizoma Alismatis extractum I;
(3) Fructus Piperis Longi is dipped to water, and steam distillation extracts Fructus Piperis Longi volatile oil, collects oil content, and is standby;
(4) Fructus Crataegi, Rhizoma Polygoni Cuspidati, the Radix Rehmanniae Preparata decoction pieces, suitably pulverizing merges, and soaks, and adds the Fructus Piperis Longi that has extracted volatile oil, decocts 3 times, filters, and merges decoction liquor, and concentrating under reduced pressure gets concentrated solution II;
(5) merge concentrated solution, drying gets the dried cream of active component;
(6) dried cream powder is broken, sieve, make soft material with 75% ethanol, the granulation of sieving, drying, granulate sprays Fructus Piperis Longi volatile oil, and mixing is made preparation.
9, method as claimed in claim 8 is wherein extracted the ethanol that used ethanol is 70%-95%.
10, have the medicine of effect for reducing blood fat and the application in the health food as claim 1,2 or 3 described compositionss in preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007101210543A CN101375978B (en) | 2007-08-29 | 2007-08-29 | Medicinal composition for lowering blood fat |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007101210543A CN101375978B (en) | 2007-08-29 | 2007-08-29 | Medicinal composition for lowering blood fat |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101375978A true CN101375978A (en) | 2009-03-04 |
| CN101375978B CN101375978B (en) | 2012-08-22 |
Family
ID=40419824
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2007101210543A Active CN101375978B (en) | 2007-08-29 | 2007-08-29 | Medicinal composition for lowering blood fat |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101375978B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103251746A (en) * | 2013-05-21 | 2013-08-21 | 翟纯杉 | Traditional Chinese medicine composition for reducing blood sugar and invigorating kidney and strengthening yang |
| CN103372072A (en) * | 2012-04-17 | 2013-10-30 | 常福厚 | Compound mixture with antihyperlipidemic effect and preparation method thereof |
| CN104056023A (en) * | 2013-03-22 | 2014-09-24 | 曹昌银 | Traditional Chinese medicine health care composition for reducing blood lipid |
| CN115120710A (en) * | 2022-07-20 | 2022-09-30 | 武汉真福医药股份有限公司 | Blood fat reducing composition and preparation method and application thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1159047C (en) * | 2002-01-18 | 2004-07-28 | 北京大学 | Composition with weight-loss and lipid-lowering effects |
| CN100484408C (en) * | 2006-11-24 | 2009-05-06 | 朱迅 | A fat-reducing health tea and preparation method thereof |
-
2007
- 2007-08-29 CN CN2007101210543A patent/CN101375978B/en active Active
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103372072A (en) * | 2012-04-17 | 2013-10-30 | 常福厚 | Compound mixture with antihyperlipidemic effect and preparation method thereof |
| CN104056023A (en) * | 2013-03-22 | 2014-09-24 | 曹昌银 | Traditional Chinese medicine health care composition for reducing blood lipid |
| CN103251746A (en) * | 2013-05-21 | 2013-08-21 | 翟纯杉 | Traditional Chinese medicine composition for reducing blood sugar and invigorating kidney and strengthening yang |
| CN115120710A (en) * | 2022-07-20 | 2022-09-30 | 武汉真福医药股份有限公司 | Blood fat reducing composition and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101375978B (en) | 2012-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101612362B (en) | Complex preparation for regulating lipid and preventing and curing heart cerebrovascular diseases and preparation method thereof | |
| CN104083727A (en) | Traditional Chinese medicine composition for nourishing and protecting liver | |
| WO2006060951A1 (en) | A pharmaceutical composition for the treatment and/or prevention of hyperlipidemia, processes for producing the same and the use thereof | |
| CN103386022B (en) | Chinese medicine composition for treating tuberculous pleurisy | |
| CN102475830B (en) | Medicinal composition for treating coronary disease and angina pectoris, preparation method thereof and preparation thereof | |
| CN102784248B (en) | Chinese medicine composition for preventing and treating alcoholic liver injury | |
| CN101375978B (en) | Medicinal composition for lowering blood fat | |
| CN101485870A (en) | Medicament for promoting digestion and expelling intestinal parasites | |
| CN1263503C (en) | 'Changyuan' capsule and preparing techniue | |
| CN101579405B (en) | Traditional Chinese medicine for treating constipation and preparation method thereof | |
| KR100585445B1 (en) | Pharmaceutical composition for the prevention and treatment of bone disease using mixed herbal medicine | |
| CN105250427A (en) | Pharmaceutical composition for treating heart diseases | |
| CN102335255B (en) | Chinese medicine for treating hyperlipidemia and fatty liver and preparation method thereof | |
| KR101864719B1 (en) | Composition for prevention and treatment of osteoporosis comprising the extract of medicinal herb mixture | |
| CN101023982B (en) | Medicine composition for treating osteoporosis | |
| CN1166397C (en) | Medicine for treating cardiovascular and cerebrovascular system disease, apoplectic sequel | |
| CN110101798B (en) | Sobering-up liver-protecting agent and preparation method thereof | |
| CN101112432A (en) | Chinese patent medicine for treating fatty liver and preparation method thereof | |
| CN100518765C (en) | A kind of traditional Chinese medicine compound preparation | |
| CN115737729B (en) | An ethnic medicinal preparation for treating osteoporosis and its preparation method | |
| CN1839931B (en) | Medicine composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN105727089A (en) | Application of medicine composition containing folium artemisiae argyi to preparing medicine for treating irritable bowel syndrome | |
| CN104857363A (en) | Combined Chinese herbal preparation for reducing blood fat and preparation method thereof | |
| CN102247545A (en) | Safflower capsule and preparation method thereof | |
| CN103933216A (en) | Compound blood pressure lowering capsules for treating metabolic hypertension, preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |